Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the…
vidofludimus calcium
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Recommended Posts
- Privosegtor optic neuritis clinical trial design gains FDA agreement
- In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS
- Bike MS in Texas – largest of events in US – raises over $9M for research, care
- Tampons could offer way to monitor multiple sclerosis nerve damage
- Life with MS is hard, but you don’t have to figure it out on your own